A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation-Reference-Cited by-同舟云学术

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

Published:2020-11 Issue:11 Volume:21 Page:1455-1464
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Prat Aleix,Guarneri Valentina,Paré Laia,Griguolo Gaia,Pascual Tomás,Dieci Maria V,Chic Núria,González-Farré Blanca,Frassoldati Antonio,Sanfeliu Esther,Cejalvo Juan M,Muñoz Montserrat,Bisagni Giancarlo,Brasó-Maristany Fara,Urso Loredana,Vidal Maria,Brandes Alba A,Adamo Barbara,Musolino Antonino,Miglietta Federica,Conte Benedetta,Oliveira Mafalda,Saura Cristina,Pernas Sònia,Alarcón Jesús,Llombart-Cussac Antonio,Cortés Javier,Manso Luis,López Rafael,Ciruelos Eva,Schettini Francesco,Villagrasa Patricia,Carey Lisa A,Perou Charles M,Piacentini Federico,D'Amico Roberto,Tagliafico Enrico,Parker Joel S,Conte Pierfranco

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831;Perez;J Clin Oncol,2014

2. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer;Prat;J Natl Cancer Inst,2014

3. A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers;Ferrari;Nat Commun,2016

4. HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade;Prat;J Natl Cancer Inst,2019

5. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade;Brasó-Maristany;Nat Commun,2020

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials;Nature Communications;2023-11-03

2. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023;Annals of Oncology;2023-11

3. Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023;Bulletin du Cancer;2023-11

4. Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review;Cancers;2023-08-30

5. DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer;Future Oncology;2023-08